Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.

Abstract: Novel anti-IL-3 antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN. The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.

Abstract: The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in a subject is described.

Abstract: The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in a subject is described.

Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.

Abstract: The present invention relates to a chemokine construct comprising a scFV anti-CD4 and a RANTES chemokine or a functional fragment thereof, whereby said chemokine construct has the structural domain form of (a) RANTES-linker-(VH) anti-CD4-linker-(VL) anti-CD4; or (b) (VL) anti-CD4-linker-(VH) anti-CD4-linker-RANTES, or (c) (VH) anti-CD4-linker-(VL) anti-CD4-linker-RANTES, whereby in the alternatives (b) and (c), the linker between (VH) anti-CD4 and RANTES or between (VL) anti-CD4 and RANTES does not terminally comprise a methionine, a lysine or an isoleucine directly adjacent to the first amino add of RANTES. Furthermore, polynucleotides encoding these chemokine constructs as well as vectors comprising these polynucleotides are disclosed. The invention also relates to specific uses of these constructs and to pharmaceutical compositions.

Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.

Abstract: The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, or (d) a cell toxin.

Abstract: The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, and (d) a cell toxin.

Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.

Abstract: The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, or (d) a cell toxin.

Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.